These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35584632)

  • 1. Quantification and targeting of elusive neurotoxic amyloid oligomers.
    Bhatt N; Kayed R
    Cell Rep Med; 2022 May; 3(5):100636. PubMed ID: 35584632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo.
    Kass B; Schemmert S; Zafiu C; Pils M; Bannach O; Kutzsche J; Bujnicki T; Willbold D
    Cell Rep Med; 2022 May; 3(5):100630. PubMed ID: 35584626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2.
    Schemmert S; Schartmann E; Honold D; Zafiu C; Ziehm T; Langen KJ; Shah NJ; Kutzsche J; Willuweit A; Willbold D
    Neurobiol Dis; 2019 Apr; 124():36-45. PubMed ID: 30391539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology.
    Schemmert S; Schartmann E; Zafiu C; Kass B; Hartwig S; Lehr S; Bannach O; Langen KJ; Shah NJ; Kutzsche J; Willuweit A; Willbold D
    Mol Neurobiol; 2019 Mar; 56(3):2211-2223. PubMed ID: 30003517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
    Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
    Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence Chemicals To Detect Insoluble and Soluble Amyloid-β Aggregates.
    Lee D; Kim SM; Kim HY; Kim Y
    ACS Chem Neurosci; 2019 Jun; 10(6):2647-2657. PubMed ID: 31009195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease.
    Kutzsche J; Schemmert S; Tusche M; Neddens J; Rabl R; Jürgens D; Brener O; Willuweit A; Hutter-Paier B; Willbold D
    Molecules; 2017 Oct; 22(10):. PubMed ID: 28994710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomic Structures of Amyloid-β Oligomers Illuminate a Neurotoxic Mechanism.
    Darling AL; Shorter J
    Trends Neurosci; 2020 Oct; 43(10):740-743. PubMed ID: 32792144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology.
    van Groen T; Schemmert S; Brener O; Gremer L; Ziehm T; Tusche M; Nagel-Steger L; Kadish I; Schartmann E; Elfgen A; Jürgens D; Willuweit A; Kutzsche J; Willbold D
    Sci Rep; 2017 Nov; 7(1):16275. PubMed ID: 29176708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing amyloid-β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry.
    Carlred L; Michno W; Kaya I; Sjövall P; Syvänen S; Hanrieder J
    J Neurochem; 2016 Aug; 138(3):469-78. PubMed ID: 27115712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of optogenetic Amyloid-β distinguishes between metabolic and physical damages in neurodegeneration.
    Lim CH; Kaur P; Teo E; Lam VYM; Zhu F; Kibat C; Gruber J; Mathuru AS; Tolwinski NS
    Elife; 2020 Mar; 9():. PubMed ID: 32228858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.
    Tolar M; Hey J; Power A; Abushakra S
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins.
    Pham E; Crews L; Ubhi K; Hansen L; Adame A; Cartier A; Salmon D; Galasko D; Michael S; Savas JN; Yates JR; Glabe C; Masliah E
    FEBS J; 2010 Jul; 277(14):3051-67. PubMed ID: 20573181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin deficiency promotes formation of toxic amyloid-β42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer's disease model.
    Imamura T; Yanagihara YT; Ohyagi Y; Nakamura N; Iinuma KM; Yamasaki R; Asai H; Maeda M; Murakami K; Irie K; Kira JI
    Neurobiol Dis; 2020 Apr; 137():104739. PubMed ID: 31927145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease?
    Klein WL
    J Alzheimers Dis; 2013; 33 Suppl 1():S49-65. PubMed ID: 22785404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Constructing Brain Aβ-Targeting Nanoparticles Loaded with EGCG for Treating Alzheimer's Disease in Mice].
    Yang P; Guo Q; Xu ST; Sheng DY; Zhang QZ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 52(4):605-611. PubMed ID: 34323038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers.
    Leithold LH; Jiang N; Post J; Ziehm T; Schartmann E; Kutzsche J; Shah NJ; Breitkreutz J; Langen KJ; Willuweit A; Willbold D
    Pharm Res; 2016 Feb; 33(2):328-36. PubMed ID: 26381279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid.
    Elfgen A; Santiago-Schübel B; Hupert M; Schemmert S; Schartmann E; Tusche M; Gering I; Zafiu C; Kutzsche J
    Eur J Pharm Sci; 2021 Jan; 156():105581. PubMed ID: 33035662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's disease as oligomeropathy.
    Ono K
    Neurochem Int; 2018 Oct; 119():57-70. PubMed ID: 28821400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening.
    Chang L; Bakhos L; Wang Z; Venton DL; Klein WL
    J Mol Neurosci; 2003; 20(3):305-13. PubMed ID: 14501013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.